The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease. Moderna's RSV shot,

After federal health officials made abrupt changes to US Covid-19 vaccine recommendations for pregnant women last month, there’s new confusion and uncertainty about who can get the shots — and some reports that patients were turned away when they tried to get vaccinated.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 18 and above. An expanded approval will help GSK better compete with rivals such as Merck's mRESVIA and Pfizer's Abrysvo after U.

In recent years COVID shots joined flu shots as an annual offering at most neighborhood pharmacies. But the current administration has thrown that into uncertainty

Just two days after retiring the entirety of the US Centers for Disease Control and Prevention’s vaccine advisory panel, US Health and Human Services Secretary Robert F. Kennedy Jr. has appointed several prominent critics of the government’s Covid-19 response to that committee.

One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck’s Gardasil vaccine, court records show.

(Reuters) -U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued with persistent conflicts of interest," puts new scrutiny on the group that recommends which shots should be administered to the American public.

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine development program will end next year.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.

(THE CONVERSATION) On June 11, 2025, Health Secretary Robert F. Kennedy Jr. announced a slate of eight new members to serve on the Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention on national vaccine policy.